241 Stock Overview
An investment holding company, engages in the pharmaceutical direct sales, pharmaceutical e-commerce platform, and healthcare and digital services businesses in Mainland China and Hong Kong. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Alibaba Health Information Technology Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$3.55 |
| 52 Week High | HK$6.30 |
| 52 Week Low | HK$2.59 |
| Beta | 1.08 |
| 11 Month Change | -7.31% |
| 3 Month Change | 21.58% |
| 1 Year Change | -22.32% |
| 33 Year Change | -52.09% |
| 5 Year Change | -59.93% |
| Change since IPO | 177.34% |
Recent News & Updates
Recent updates
Earnings Tell The Story For Alibaba Health Information Technology Limited (HKG:241) As Its Stock Soars 30%
Oct 18
What Does Alibaba Health Information Technology Limited's (HKG:241) Share Price Indicate?
Sep 23Alibaba Health Information Technology (HKG:241) Is Looking To Continue Growing Its Returns On Capital
Jul 03After Leaping 26% Alibaba Health Information Technology Limited (HKG:241) Shares Are Not Flying Under The Radar
Jun 07Alibaba Health Information Technology's (HKG:241) Solid Earnings Are Supported By Other Strong Factors
Jun 06Risks Still Elevated At These Prices As Alibaba Health Information Technology Limited (HKG:241) Shares Dive 26%
Apr 21Is Now The Time To Look At Buying Alibaba Health Information Technology Limited (HKG:241)?
Apr 16Alibaba Health Information Technology (HKG:241) Might Have The Makings Of A Multi-Bagger
Mar 29Is There An Opportunity With Alibaba Health Information Technology Limited's (HKG:241) 36% Undervaluation?
Mar 12With A 25% Price Drop For Alibaba Health Information Technology Limited (HKG:241) You'll Still Get What You Pay For
Jan 17Is Now An Opportune Moment To Examine Alibaba Health Information Technology Limited (HKG:241)?
Jan 07Returns On Capital Are Showing Encouraging Signs At Alibaba Health Information Technology (HKG:241)
Dec 15Shareholders Should Be Pleased With Alibaba Health Information Technology Limited's (HKG:241) Price
Sep 28Alibaba Health Information Technology Limited's (HKG:241) Intrinsic Value Is Potentially 25% Below Its Share Price
Jul 02Is Alibaba Health Information Technology Limited (HKG:241) Potentially Undervalued?
Jun 11Estimating The Fair Value Of Alibaba Health Information Technology Limited (HKG:241)
Jun 22Is There An Opportunity With Alibaba Health Information Technology Limited's (HKG:241) 49% Undervaluation?
Dec 01Alibaba Health Information Technology (HKG:241) Is Looking To Continue Growing Its Returns On Capital
Oct 15Estimating The Fair Value Of Alibaba Health Information Technology Limited (HKG:241)
Aug 12Alibaba Health Information Technology (HKG:241) Is Doing The Right Things To Multiply Its Share Price
Jun 25These Analysts Just Made A Huge Downgrade To Their Alibaba Health Information Technology Limited (HKG:241) EPS Forecasts
May 30Earnings Report: Alibaba Health Information Technology Limited Missed Revenue Estimates By 6.8%
May 27The Return Trends At Alibaba Health Information Technology (HKG:241) Look Promising
Mar 23Should You Be Adding Alibaba Health Information Technology (HKG:241) To Your Watchlist Today?
Mar 05How Much Are Alibaba Health Information Technology Limited (HKG:241) Insiders Taking Off The Table?
Feb 15Are Alibaba Health Information Technology's (HKG:241) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Jan 31
If You Had Bought Alibaba Health Information Technology (HKG:241) Stock Three Years Ago, You Could Pocket A 457% Gain Today
Dec 31Has Alibaba Health Information Technology Limited's (HKG:241) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
Dec 16Will Alibaba Health Information Technology's (HKG:241) Growth In ROCE Persist?
Dec 01Shareholder Returns
| 241 | HK Consumer Retailing | HK Market | |
|---|---|---|---|
| 7D | -6.6% | -3.0% | -0.6% |
| 1Y | -22.3% | -32.1% | 9.6% |
Return vs Industry: 241 exceeded the Hong Kong Consumer Retailing industry which returned -32.1% over the past year.
Return vs Market: 241 underperformed the Hong Kong Market which returned 9.6% over the past year.
Price Volatility
| 241 volatility | |
|---|---|
| 241 Average Weekly Movement | 13.9% |
| Consumer Retailing Industry Average Movement | 8.2% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 19.2% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 241's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 241's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 1,422 | Difan Shen | www.alihealth.cn |
Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical direct sales, pharmaceutical e-commerce platform, and healthcare and digital services businesses in Mainland China and Hong Kong. The company offers a range of prescription and over-the-counter drugs, nutritional supplements, medical devices, contact lenses, health food, adult and family planning products, healthcare and skincare products, and various other health-related products. It also provides medical and healthcare services, including medical checkups, nucleic acid testing, medical consultation, appointment-booking, vaccination, dental care, mental care, optometry, and nursing services, as well as traditional Chinese medicines.
Alibaba Health Information Technology Limited Fundamentals Summary
| 241 fundamental statistics | |
|---|---|
| Market cap | HK$57.09b |
| Earnings (TTM) | HK$1.30b |
| Revenue (TTM) | HK$30.45b |
44.0x
P/E Ratio1.9x
P/S RatioIs 241 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 241 income statement (TTM) | |
|---|---|
| Revenue | CN¥28.34b |
| Cost of Revenue | CN¥21.78b |
| Gross Profit | CN¥6.56b |
| Other Expenses | CN¥5.35b |
| Earnings | CN¥1.21b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.075 |
| Gross Margin | 23.15% |
| Net Profit Margin | 4.26% |
| Debt/Equity Ratio | 0% |
How did 241 perform over the long term?
See historical performance and comparison